| |
| SEPTEMBER
2011 |
|
|
Top ten generic pharma
We profile the top ten generic companies most
likely to benefit as Big Pharma patents expire.
view pdf
Healthcare opportunities abound
How consumers look after their
health has many implications
for the pharmaceutical industry.
Deloitte’s latest Global Survey
of Health Consumers reveals
the behaviours, attitudes and
unmet needs of consumers
in 12 countries.
view pdf
|
Publish and be damned
The pharmaceutical industry
faces growing public demand for
greater transparency in the
publication of drug trial results,
but, says the EFPIA, the risk
of misinterpretation also needs
to be considered.
view pdf
|
The cost of
a deep cut
Cost-containment is a major thrust
area for policy reforms of
pharmaceutical reimbursement and
pricing in Europe, writes Ranjith
Gopinathan of Frost & Sullivan.
view pdf |
Greening the industry
Pfizer discusses the importance of
staff participation in sustainability
programmes and the significant
strides the company has made in
green chemistry and green design.
view pdf
A vital cog in the machine
Given the complex manufacturing
process of biopharmaceuticals,
achieving operational excellence is
an organisational challenge. Dr
André Overmeyer of Merck Serono
talks to Nic Paton about the benefits
of reducing the cost of goods sold.
view pdf
|
Suspended solutions
Overcoming solubility issues is one
of the most common formulation
challenges facing pharmaceutical
businesses today. Bayer
HealthCare’s Andreas Ohm
explains how his company is
addressing the problem.
view pdf
Ready for take-off
Controlled-release drugs have been
around for some time and have
many benefits, particularly for
patients with chronic or
autoimmune diseases, but ongoing
research has revealed that this
market’s potential is only now
about to take off.
view pdf
|
Best laid plans
From securing a robust supply
chain to encountering different
comparator drug formulations,
there are a swathe of variables
to consider when conducting
pharmaceutical research. But
what is the best way to overcome
such obstacles? Nic Paton asks
H Lundbeck’s Dorthe Lerche
Berg what strategies are
needed to ensure a successful
comparator drugs trial.
view pdf |
Play it cool
Logistics systems in the developed
world continue to evolve at
breakneck speed, but their
counterparts in emerging nations
are lagging behind, meaning drugs
and vaccines are not being
delivered in optimum condition or
in the correct quantities. Elly Earls
talks to John Lloyd of Project
Optimize about the initiatives
underway to change this.
view pdf |
|
Open sesame
AstraZeneca outlines its latest
strategic alliances in discovery
research and innovation.
view pdf |
In the pipeline
According to GlobalData, 2011
will be another successful year
for biological approvals.
view pdf |
Best medicine
Dr Antony Fake and Jacqueline
Sawyer discuss the benefits
of the WHO’s Prequalification
of Medicines Programme.
view pdf |
On the right track
How pharma manufacturers
can select the right excipient
for their formulation.
view pdf |
Clouds of change
Mollie Shields-Uehling, SAFEBioPharma
Association, on using
a cloud computing method to
conduct a clinical trial.
view pdf |
Mixed messages
Novo Nordisk’s Kim Steffensen
on how to successfully work
with CMOs in emerging markets.
view pdf |
Perfect fit
Abi Millar talks to Frances Grote,
Millennium Pharmaceuticals,
about how to achieve excellence
within outsourced relationships
view pdf |
|
|
